Sorrento Therapeutics (NASDAQ:SRNE) Coverage Initiated at StockNews.com

Posted by on Feb 5th, 2025

Equities researchers at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Trading Up 1,150.0 %

SRNE opened at $0.01 on Monday. Sorrento Therapeutics has a twelve month low of $0.00 and a twelve month high of $0.10.

About Sorrento Therapeutics

(Get Free Report)

Sorrento Therapeutics, Inc, a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.

Read More

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.